Solidarity (remdesivir)
Trial question
What is the role of remdesivir in patients hospitalized with COVID-19?
Study design
Multi-center
Open label
RCT
Population
Characteristics of study participants
37.0% female
63.0% male
N = 8275
8275 patients (3035 female, 5240 male).
Inclusion criteria: adult patients hospitalized with COVID-19.
Key exclusion criteria: serious chronic liver; heart disease; pregnancy.
Interventions
N=4146 remdesivir (10 daily infusions unless discharged earlier).
N=4129 no remdesivir (standard of care alone).
Primary outcome
In-hospital mortality
14.5%
15.6%
15.6 %
11.7 %
7.8 %
3.9 %
0.0 %
Remdesivir
No
remdesivir
No significant
difference ↔
No significant difference in in-hospital mortality (14.5% vs. 15.6%; RR 0.91, 95% CI 0.82 to 1.02).
Secondary outcomes
Significant decrease in progression to ventilation (14.1% vs. 15.7%; RR 0.88, 95% CI 0.77 to 1).
Significant decrease in death or progression to ventilation (19.6% vs. 22.5%; RR 0.84, 95% CI 0.75 to 0.93).
Conclusion
In adult patients hospitalized with COVID-19, remdesivir was not superior to no remdesivir with respect to a in-hospital mortality.
Reference
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-1953.
Open reference URL